Skip to main content

Academy Urges CMS to Address Prior Authorization, Other Burdens in Medicare Advantage Plans

We raised concerns about how these delays in treatment exacerbate health care disparities.

The Academy used a recent call for input on improvements to the Medicare Advantage Program to reiterate our concerns about administrative burdens. In comments submitted to the Centers for Medicare & Medicaid Services (CMS), we urged the agency to increase oversight of plans and reinstate a ban on step therapy.

CMS recently sought public comment on ways to improve the Medicare Advantage program. The agency wanted input on several goals:

  • Improve health equity, given growing awareness of disparities among Medicare patients.
  • Expand access to care, especially for underserved communities.
  • Encourage innovation to improve the quality of care provided.

CMS also sought input on how to improve its partner relationships and ensure Medicare Advantage remains affordable and sustainable.

The Academy focused on three issues in our comments: , step therapy and onerous record requests. We noted the many issues caused by Aetna’s albeit short-lived .

We also highlighted the growing disparities caused in 2019 when CMS allowed step therapy to return to Medicare Advantage plans for Part B medications. This policy delays care for Medicare Advantage and harms seriously ill patients. Compared with fee-for-service patients, they are disproportionately lower-income, Black or Latino and more often dually enrolled in Medicaid.

We urged CMS to reinstate its previous ban on step therapy, to ensure all Medicare patients get equal and timely access to the treatments they need.

Lastly, the Academy urged CMS to address burdensome record requests to medical practices. These requests often fail to clarify or address insurers’ underlying goals, and they may also contribute to dubious billing practices by Medicare Advantage plans.

We will continue to use every opportunity to address the administrative burdens you face and the ways they delay patients’ timely access to medically necessary treatment.

Related Stories

Member exclusive - Locked Fallback image

CMS Tests Prior Authorization for Some ASC Services

The Centers for Medicare & Medicaid Services (CMS) has introduced a new pilot program requiring prior authorization (PA) for fee-for-service Medicare for certain services in ambulatory surgical centers (ASCs).
Member exclusive - Locked Fallback image

Advocacy Works: Academy Pushes Humana to Correct 1.8 Million Denied Claims

Responding to members, the Academy fought Humana's mass denials and won. Here's what your practice needs to know to recover affected payments.
Member exclusive - Locked Fallback image

Advocacy Works: CMS Delays ASC Prior Authorization Pilot

With the help of the American Society of Ophthalmic Plastic and Reconstructive Surgery, the Outpatient Ophthalmic Surgery Society, and the North American Neuro-Ophthalmology Society, the Academy has persuaded the Centers for Medicare & Medicaid Services (CMS) to delay the start of the prior authorization (PA) pilot in ambulatory surgical centers.

Latest Updates

Member exclusive - Locked Fallback image

Milestone Moment: Seniors' Act Advances Unanimously Through Ways & Means Committee

Thanks to Academy advocacy and leadership, and the voices of members like you, the Seniors’ Act cleared a major hurdle in reforming prior authorization in Medicare Advantage. Let’s keep pushing until it becomes law.

Member exclusive - Locked Fallback image

2027 Fee Schedule Proposes Cutting Pay to Physicians by 1.68%

The Centers for Medicare & Medicaid Services (CMS) has released its proposed Medicare Physician Fee Schedule for 2027. Here are the highlights based on the Academy’s analysis. The Academy will work with our advocacy partners to ensure finalized policies support our members and their patients.

Member exclusive - Locked Fallback image

Academy Rallies Ophthalmology to Fight Proposed Drug-delivery Coverage Cuts

Leading the profession's response, the Academy united ophthalmic societies to formally oppose Medicare's proposed restrictions on intraocular drug-delivery implant coverage.